Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion

The Food and Drug Administration issued guidance for evaluating the cardiovascular risk of new diabetes mellitus drugs in 2008. Accumulating evidence from several completed trials conducted within this framework raises questions as to whether requiring safety outcome studies for all new diabetes mel...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur Heart J Cardiovasc Pharmacother
Main Authors: Zannad, Faiez, Stough, Wendy Gattis, Lipicky, Raymond J., Tamargo, Juan, Bakris, George L., Borer, Jeffrey S., Alonso García, Maria de los Angeles, Hadjadj, Samy, Koenig, Wolfgang, Kupfer, Stuart, McCullough, Peter A., Mosenzon, Ofri, Pocock, Stuart, Scheen, André J., Sourij, Harald, Van der Schueren, Bart, Stahre, Christina, White, William B., Calvo, Gonzalo
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2016
Assuntos:
Reviews
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4907355/
https://ncbi.nlm.nih.gov/pubmed/27418973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ehjcvp/pvw007
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares